Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Misses Estimates By $0.37 EPS

Keros Therapeutics (NASDAQ:KROS) released its earnings results on Wednesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37), FiscalAI reports. The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.Keros Therapeutics’s revenue was down 87.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.14) earnings per share.

Keros Therapeutics Stock Down 3.5%

Shares of Keros Therapeutics stock opened at $11.30 on Monday. The business has a fifty day simple moving average of $17.41 and a 200-day simple moving average of $17.07. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $22.55. The firm has a market cap of $344.27 million, a price-to-earnings ratio of 6.21 and a beta of 0.87.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen lowered Keros Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research downgraded shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Bank of America raised their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $21.86.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the last quarter. New York State Common Retirement Fund boosted its stake in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new stake in Keros Therapeutics in the 3rd quarter valued at $176,000. Finally, XTX Topco Ltd acquired a new position in shares of Keros Therapeutics in the 4th quarter valued at $212,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.